Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic hematopoietic stem cell transplantation combined with CD19 CAR-T for B-cell hematologic malignancies
ChiCTR-OIC-17012374Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Aug 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in B-cell hematologic malignancies, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Complete remission rate and Progression-free survival. Started Aug 2017; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
B-cell hematologic malignancies
Beyond the preview
Go deeper on ChiCTR-OIC-17012374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17012374.